HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Mernagh, P Articles by Weston, A R Search for Related Content PubMed PubMed Citation Articles by Mernagh, P Articles by Weston, A R

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

Health Technology Analysts Pty Ltd, PO Box 133, Balmain, Sydney 2041, Australia, ¹ Department of Nuclear Medicine, University of Cologne, Cologne, Germany, ² Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany and ³ Department of Medicine, University of Florida, Gainesville, Florida, USA

(Correspondence should be addressed to P Mernagh; Email: pmernagh{at}htanalysts.com)

Objective: This investigation evaluated the cost-effectiveness of radioiodine remnant ablation following preparation with recombinant human TSH (rhTSH), compared with the standard preparation, whereby patients are rendered hypothyroid.

Design: The economic evaluation relates to patients with well differentiated thyroid cancer who have undergone thyroidectomy, but have no metastases. The evaluation takes a societal perspective, considering costs and benefits to all parties. The benefits were expressed in units of quality-adjusted life years (QALY), so differences in life expectancy were captured with consideration of quality of life.

Methods: A lifetime Markov model with Monte Carlo simulation of 100 000 patients was used to assess cost per QALY gained. The clinical inputs were sourced from a multi-centre, randomised controlled trial comparing remnant ablation success after rhTSH-preparation with hypothyroid preparation. The model applied German unit costs, however, the structure is generalisable to other jurisdictions. The additional cost of rhTSH procurement and administration is considered relative to the clinical benefits and cost offsets. These included avoidance of hypothyroidism, increased work productivity, earlier discharge from radioprotection and a theoretical reduction in the risk of secondary malignancy. The latter two benefits relate to faster radioiodine clearance after rhTSH preparation.

Results: The additional benefits of rhTSH (0.0495 QALY) are obtained with an incremental societal cost of 47, equating to an incremental cost per QALYof 958. Sensitivity analyses had only a modest impact upon cost-effectiveness, with all one-way sensitivity results remaining under 15 000/QALY.

Conclusions: The use of rhTSH prior to radioiodine ablation represents good value-for-money with the benefits to patient and society obtained at modest net cost.

This article has been cited by other articles:

				I Borget, C Corone, M Nocaudie, M Allyn, S Iacobelli, M Schlumberger, and G De Pouvourville Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal Eur. J. Endocrinol., May 1, 2007; 156(5): 531 - 538. [Abstract] [Full Text] [PDF]